MXPA04006206A - Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico. - Google Patents

Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.

Info

Publication number
MXPA04006206A
MXPA04006206A MXPA04006206A MXPA04006206A MXPA04006206A MX PA04006206 A MXPA04006206 A MX PA04006206A MX PA04006206 A MXPA04006206 A MX PA04006206A MX PA04006206 A MXPA04006206 A MX PA04006206A MX PA04006206 A MXPA04006206 A MX PA04006206A
Authority
MX
Mexico
Prior art keywords
alkyl
carbamate
cycloalkyl
several
optionally substituted
Prior art date
Application number
MXPA04006206A
Other languages
English (en)
Inventor
Garcia Adnres Fernandez
Original Assignee
S A L V A T Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S A L V A T Lab Sa filed Critical S A L V A T Lab Sa
Publication of MXPA04006206A publication Critical patent/MXPA04006206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Carbamato de formula (I), donde R1, R2 y R3 son H, OH, NO2, SH, CN, F, CL, Br, I, CONH2, (C1-C4)-alcoxicarbonilo, (c1-C4)-alquiltio, (C1-C4)-alquilsulfinilo, (C1-C4)-alquilsulfonilo, (C1-C4)-alxcoxi opcionalmente sustituido con uno o varios F, y (C1-C4)-alquilo opcionalemente sustituido con uno o varios F o OH; R4 es cicloalquilo, fenil, heteroaril o un sistema biciclico; R5 es cicloalquilo, (C5-C10)-alquilo, un (C1-C10)-alquilo sustituido; y X es un anion fisiologicamente aceptable. Los carbamatos de formula (I) on antagonistas del receptor M3 selectivos versus del receptor M2 y pueden ser utilizados para el tratamiento de la incontinencia urinaria (en particular la debida inestabilidad vesical), del sindrome del intestino irritable y de enfermedades de las vias respiratorias (en particular, la enfermedad pulmonar obstructiva cronica, la bronquitis cronica, el asma, el enfisema y la rinitis), asi como para intervenciones oftalmicas.
MXPA04006206A 2001-12-20 2002-12-18 Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico. MXPA04006206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200043 2001-12-20
PCT/EP2002/014470 WO2003053966A2 (en) 2001-12-20 2002-12-18 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA04006206A true MXPA04006206A (es) 2004-12-06

Family

ID=32480019

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006206A MXPA04006206A (es) 2001-12-20 2002-12-18 Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.

Country Status (21)

Country Link
US (1) US7452904B2 (es)
EP (1) EP1461336B1 (es)
JP (1) JP4505227B2 (es)
KR (1) KR100944580B1 (es)
CN (1) CN1832948B (es)
BR (1) BR0215348A (es)
CA (1) CA2470956C (es)
EA (1) EA006505B1 (es)
ES (1) ES2425347T3 (es)
GE (1) GEP20063958B (es)
HK (1) HK1070057A1 (es)
HR (1) HRP20040661A2 (es)
HU (1) HUP0500107A3 (es)
IL (1) IL162596A0 (es)
MA (1) MA26385A1 (es)
MX (1) MXPA04006206A (es)
NO (1) NO329664B1 (es)
PL (1) PL211250B1 (es)
RS (1) RS52522B (es)
UA (1) UA76571C2 (es)
WO (1) WO2003053966A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20122417U1 (de) * 2000-06-27 2005-08-04 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Von Arylalkylaminen abgeleitete Carbamate
IL156499A0 (en) * 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
ES2313401T3 (es) 2004-07-30 2009-03-01 Laboratorios Salvat, S.A. Derivados de tirosina como moduladores de ppar-gamma.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002805A (es) 2005-09-21 2008-04-07 Pfizer Ltd Derivados de carboxamida como antagonistas del receptor muscarinico.
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
EP2076261A2 (en) * 2006-10-03 2009-07-08 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
EP2080523A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2080507A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2585458B1 (en) 2010-06-22 2015-01-07 Chiesi Farmaceutici S.p.A. Alkaloid aminoester derivatives and medicinal compositions thereof
CN102947298B (zh) 2010-06-22 2016-03-02 奇斯药制品公司 生物碱氨基酯衍生物及其药物组合物
CA2803459A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
AU2011269238A1 (en) 2010-06-22 2013-01-10 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2640721B1 (en) 2010-11-16 2018-06-06 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors
RU2585767C2 (ru) 2010-11-26 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные глицина и их применение в качестве антагонистов мускариновых рецепторов
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
RU2611627C2 (ru) 2011-04-29 2017-02-28 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидный эфир и карбаматные производные и их медицинские композиции
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
CN104011043B (zh) 2011-12-30 2016-11-16 奇斯药制品公司 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
KR20240052079A (ko) 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법
US11311619B2 (en) 2016-04-28 2022-04-26 7 Hills Pharma Inc. and Texas Heart Institute Integrin activator vaccine compositions
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0495071A (ja) * 1990-08-10 1992-03-27 Kyorin Pharmaceut Co Ltd カルバミン酸誘導体
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MXPA02005596A (es) * 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
DE20122417U1 (de) * 2000-06-27 2005-08-04 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Von Arylalkylaminen abgeleitete Carbamate
IL156499A0 (en) * 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists

Also Published As

Publication number Publication date
NO20043064L (no) 2004-09-17
KR100944580B1 (ko) 2010-02-25
HK1070057A1 (es) 2005-06-10
HUP0500107A3 (en) 2011-05-30
HUP0500107A2 (hu) 2005-05-30
BR0215348A (pt) 2004-11-16
MA26385A1 (fr) 2004-11-01
PL211250B1 (pl) 2012-04-30
WO2003053966A2 (en) 2003-07-03
CN1832948B (zh) 2011-06-15
AU2002361158A1 (en) 2003-07-09
RS52522B (en) 2013-04-30
US7452904B2 (en) 2008-11-18
HRP20040661A2 (en) 2005-06-30
WO2003053966A8 (en) 2004-06-24
GEP20063958B (en) 2006-11-10
ES2425347T3 (es) 2013-10-14
EP1461336A2 (en) 2004-09-29
CA2470956A1 (en) 2003-07-03
PL370972A1 (en) 2005-06-13
JP2005516954A (ja) 2005-06-09
UA76571C2 (en) 2006-08-15
CA2470956C (en) 2011-08-02
RS53904A (en) 2006-12-15
EA006505B1 (ru) 2005-12-29
EA200400832A1 (ru) 2004-12-30
NO329664B1 (no) 2010-11-29
JP4505227B2 (ja) 2010-07-21
CN1832948A (zh) 2006-09-13
IL162596A0 (en) 2005-11-20
US20050043349A1 (en) 2005-02-24
KR20040091614A (ko) 2004-10-28
EP1461336B1 (en) 2013-05-22
WO2003053966A3 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
MXPA04006206A (es) Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
AP1420A (en) Carbamates derived from arylalkylamines.
NO20061454L (no) Compounds having CRTH2 antagonist activity
MY140021A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
NO20052883L (no) Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom.
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20050164L (no) Nye quinuklidin-amid-derivater
MY148988A (en) Terphenyl derivatives for treatment of alzheimer&#39;s disease
WO2006002434A3 (en) Novel indazole carboxamides and their use
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
WO2005079496A3 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
UA93032C2 (uk) ПОХІДНІ ТРИАЗОЛОПІРИДИНІЛСУЛЬФАНІЛУ ЯК ІНГІБІТОРИ р38 MAP КІНАЗИ
TW200744606A (en) Use of tiotropium salts in the treatment of severe persistent asthma
MXPA05011059A (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
WO2005048932A3 (en) N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
DK1776366T3 (da) Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
CA2534550A1 (en) 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
WO2006000324A3 (en) New mao-b inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration